Clinical management of COVID-19.
Identifieur interne : 000267 ( Main/Exploration ); précédent : 000266; suivant : 000268Clinical management of COVID-19.
Auteurs : George M. Varghese [Inde] ; Rebecca John [Inde] ; Abi Manesh [Inde] ; Rajiv Karthik [Inde] ; O C Abraham [Inde]Source :
- The Indian journal of medical research [ 0971-5916 ] ; 2020.
Descripteurs français
- KwdFr :
- AMP (analogues et dérivés), AMP (usage thérapeutique), Acuité des besoins du patient (MeSH), Alanine (analogues et dérivés), Alanine (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Antipaludiques (usage thérapeutique), Antiviraux (usage thérapeutique), Betacoronavirus (MeSH), Choc (thérapie), Hormones corticosurrénaliennes (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Immunisation passive (MeSH), Infections à coronavirus (diagnostic), Infections à coronavirus (thérapie), Maladie grave (MeSH), Manipulation d'échantillons (MeSH), Pandémies (MeSH), Pneumopathie virale (diagnostic), Pneumopathie virale (thérapie), Populations vulnérables (MeSH), Prise en charge des voies aériennes (MeSH), Évaluation des symptômes (MeSH).
- MESH :
- analogues et dérivés : AMP, Alanine.
- diagnostic : Infections à coronavirus, Pneumopathie virale.
- thérapie : Choc, Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : AMP, Alanine, Anticorps monoclonaux humanisés, Antipaludiques, Antiviraux, Hormones corticosurrénaliennes, Hydroxychloroquine.
- Acuité des besoins du patient, Betacoronavirus, Humains, Immunisation passive, Maladie grave, Manipulation d'échantillons, Pandémies, Populations vulnérables, Prise en charge des voies aériennes, Évaluation des symptômes.
English descriptors
- KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (therapeutic use), Adrenal Cortex Hormones (therapeutic use), Airway Management (MeSH), Alanine (analogs & derivatives), Alanine (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antimalarials (therapeutic use), Antiviral Agents (therapeutic use), Betacoronavirus (MeSH), Coronavirus Infections (diagnosis), Coronavirus Infections (therapy), Critical Illness (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Immunization, Passive (MeSH), Pandemics (MeSH), Patient Acuity (MeSH), Pneumonia, Viral (diagnosis), Pneumonia, Viral (therapy), Shock (therapy), Specimen Handling (MeSH), Symptom Assessment (MeSH), Vulnerable Populations (MeSH).
- MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , therapeutic use : Adenosine Monophosphate, Adrenal Cortex Hormones, Alanine, Antibodies, Monoclonal, Humanized, Antimalarials, Antiviral Agents, Hydroxychloroquine.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- therapy : Coronavirus Infections, Pneumonia, Viral, Shock.
- Airway Management, Betacoronavirus, Critical Illness, Humans, Immunization, Passive, Pandemics, Patient Acuity, Specimen Handling, Symptom Assessment, Vulnerable Populations.
Abstract
The novel coronavirus disease 2019 (COVID-19) with its early origin from Wuhan city in China has evolved into a global pandemic. Maximal precautionary measures and resources have been put forward by most nations in war footing to mitigate transmission and decrease fatality rates. This article was aimed to review the evidence on clinical management and to deal with the identification of high-risk groups, warning signs, appropriate investigations, proper sample collection for confirmation, general and specific treatment measures, strategies as well as infection control in the healthcare settings. Advanced age, cardiovascular disease, diabetes, hypertension and cancer have been found to be the risk factors for severe disease. Fever lasting for >five days with tachypnoea, tachycardia or hypotension are indications for urgent attention and hospitalization in a patient with suspected COVID-19. At present, reverse transcription-polymerase chain reaction (RT-PCR) from the upper respiratory tract samples is the diagnostic test of choice. While many drugs have shown in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there are insufficient clinical data to promote or dissuade their usage. Among the currently available drugs, hydroxychloroquine and lopinavir/ritonavir may be considered for patients with severe COVID-19 infection, awaiting further clinical trials. Stringent droplet and contact precautions will protect healthcare workers against most clinical exposures to COVID-19.
DOI: 10.4103/ijmr.IJMR_957_20
PubMed: 32611911
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical management of COVID-19.</title><author><name sortKey="Varghese, George M" sort="Varghese, George M" uniqKey="Varghese G" first="George M" last="Varghese">George M. Varghese</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu</wicri:regionArea><wicri:noRegion>Tamil Nadu</wicri:noRegion></affiliation></author><author><name sortKey="John, Rebecca" sort="John, Rebecca" uniqKey="John R" first="Rebecca" last="John">Rebecca John</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu</wicri:regionArea><wicri:noRegion>Tamil Nadu</wicri:noRegion></affiliation></author><author><name sortKey="Manesh, Abi" sort="Manesh, Abi" uniqKey="Manesh A" first="Abi" last="Manesh">Abi Manesh</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu</wicri:regionArea><wicri:noRegion>Tamil Nadu</wicri:noRegion></affiliation></author><author><name sortKey="Karthik, Rajiv" sort="Karthik, Rajiv" uniqKey="Karthik R" first="Rajiv" last="Karthik">Rajiv Karthik</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu</wicri:regionArea><wicri:noRegion>Tamil Nadu</wicri:noRegion></affiliation></author><author><name sortKey="Abraham, O C" sort="Abraham, O C" uniqKey="Abraham O" first="O C" last="Abraham">O C Abraham</name><affiliation wicri:level="1"><nlm:affiliation>Department of General Medicine & Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of General Medicine & Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu</wicri:regionArea><wicri:noRegion>Tamil Nadu</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32611911</idno><idno type="pmid">32611911</idno><idno type="doi">10.4103/ijmr.IJMR_957_20</idno><idno type="wicri:Area/Main/Corpus">000086</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000086</idno><idno type="wicri:Area/Main/Curation">000086</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000086</idno><idno type="wicri:Area/Main/Exploration">000086</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical management of COVID-19.</title><author><name sortKey="Varghese, George M" sort="Varghese, George M" uniqKey="Varghese G" first="George M" last="Varghese">George M. Varghese</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu</wicri:regionArea><wicri:noRegion>Tamil Nadu</wicri:noRegion></affiliation></author><author><name sortKey="John, Rebecca" sort="John, Rebecca" uniqKey="John R" first="Rebecca" last="John">Rebecca John</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu</wicri:regionArea><wicri:noRegion>Tamil Nadu</wicri:noRegion></affiliation></author><author><name sortKey="Manesh, Abi" sort="Manesh, Abi" uniqKey="Manesh A" first="Abi" last="Manesh">Abi Manesh</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu</wicri:regionArea><wicri:noRegion>Tamil Nadu</wicri:noRegion></affiliation></author><author><name sortKey="Karthik, Rajiv" sort="Karthik, Rajiv" uniqKey="Karthik R" first="Rajiv" last="Karthik">Rajiv Karthik</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu</wicri:regionArea><wicri:noRegion>Tamil Nadu</wicri:noRegion></affiliation></author><author><name sortKey="Abraham, O C" sort="Abraham, O C" uniqKey="Abraham O" first="O C" last="Abraham">O C Abraham</name><affiliation wicri:level="1"><nlm:affiliation>Department of General Medicine & Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of General Medicine & Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu</wicri:regionArea><wicri:noRegion>Tamil Nadu</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Indian journal of medical research</title><idno type="ISSN">0971-5916</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term><term>Adenosine Monophosphate (therapeutic use)</term><term>Adrenal Cortex Hormones (therapeutic use)</term><term>Airway Management (MeSH)</term><term>Alanine (analogs & derivatives)</term><term>Alanine (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antimalarials (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (therapy)</term><term>Critical Illness (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Immunization, Passive (MeSH)</term><term>Pandemics (MeSH)</term><term>Patient Acuity (MeSH)</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (therapy)</term><term>Shock (therapy)</term><term>Specimen Handling (MeSH)</term><term>Symptom Assessment (MeSH)</term><term>Vulnerable Populations (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>AMP (analogues et dérivés)</term><term>AMP (usage thérapeutique)</term><term>Acuité des besoins du patient (MeSH)</term><term>Alanine (analogues et dérivés)</term><term>Alanine (usage thérapeutique)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antipaludiques (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Betacoronavirus (MeSH)</term><term>Choc (thérapie)</term><term>Hormones corticosurrénaliennes (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Immunisation passive (MeSH)</term><term>Infections à coronavirus (diagnostic)</term><term>Infections à coronavirus (thérapie)</term><term>Maladie grave (MeSH)</term><term>Manipulation d'échantillons (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (diagnostic)</term><term>Pneumopathie virale (thérapie)</term><term>Populations vulnérables (MeSH)</term><term>Prise en charge des voies aériennes (MeSH)</term><term>Évaluation des symptômes (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term><term>Adrenal Cortex Hormones</term><term>Alanine</term><term>Antibodies, Monoclonal, Humanized</term><term>Antimalarials</term><term>Antiviral Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>AMP</term><term>Alanine</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Shock</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Choc</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>AMP</term><term>Alanine</term><term>Anticorps monoclonaux humanisés</term><term>Antipaludiques</term><term>Antiviraux</term><term>Hormones corticosurrénaliennes</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Airway Management</term><term>Betacoronavirus</term><term>Critical Illness</term><term>Humans</term><term>Immunization, Passive</term><term>Pandemics</term><term>Patient Acuity</term><term>Specimen Handling</term><term>Symptom Assessment</term><term>Vulnerable Populations</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Acuité des besoins du patient</term><term>Betacoronavirus</term><term>Humains</term><term>Immunisation passive</term><term>Maladie grave</term><term>Manipulation d'échantillons</term><term>Pandémies</term><term>Populations vulnérables</term><term>Prise en charge des voies aériennes</term><term>Évaluation des symptômes</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The novel coronavirus disease 2019 (COVID-19) with its early origin from Wuhan city in China has evolved into a global pandemic. Maximal precautionary measures and resources have been put forward by most nations in war footing to mitigate transmission and decrease fatality rates. This article was aimed to review the evidence on clinical management and to deal with the identification of high-risk groups, warning signs, appropriate investigations, proper sample collection for confirmation, general and specific treatment measures, strategies as well as infection control in the healthcare settings. Advanced age, cardiovascular disease, diabetes, hypertension and cancer have been found to be the risk factors for severe disease. Fever lasting for >five days with tachypnoea, tachycardia or hypotension are indications for urgent attention and hospitalization in a patient with suspected COVID-19. At present, reverse transcription-polymerase chain reaction (RT-PCR) from the upper respiratory tract samples is the diagnostic test of choice. While many drugs have shown in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there are insufficient clinical data to promote or dissuade their usage. Among the currently available drugs, hydroxychloroquine and lopinavir/ritonavir may be considered for patients with severe COVID-19 infection, awaiting further clinical trials. Stringent droplet and contact precautions will protect healthcare workers against most clinical exposures to COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32611911</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0971-5916</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>The Indian journal of medical research</Title><ISOAbbreviation>Indian J. Med. Res.</ISOAbbreviation></Journal><ArticleTitle>Clinical management of COVID-19.</ArticleTitle><Pagination><MedlinePgn>401-410</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/ijmr.IJMR_957_20</ELocationID><Abstract><AbstractText>The novel coronavirus disease 2019 (COVID-19) with its early origin from Wuhan city in China has evolved into a global pandemic. Maximal precautionary measures and resources have been put forward by most nations in war footing to mitigate transmission and decrease fatality rates. This article was aimed to review the evidence on clinical management and to deal with the identification of high-risk groups, warning signs, appropriate investigations, proper sample collection for confirmation, general and specific treatment measures, strategies as well as infection control in the healthcare settings. Advanced age, cardiovascular disease, diabetes, hypertension and cancer have been found to be the risk factors for severe disease. Fever lasting for >five days with tachypnoea, tachycardia or hypotension are indications for urgent attention and hospitalization in a patient with suspected COVID-19. At present, reverse transcription-polymerase chain reaction (RT-PCR) from the upper respiratory tract samples is the diagnostic test of choice. While many drugs have shown in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there are insufficient clinical data to promote or dissuade their usage. Among the currently available drugs, hydroxychloroquine and lopinavir/ritonavir may be considered for patients with severe COVID-19 infection, awaiting further clinical trials. Stringent droplet and contact precautions will protect healthcare workers against most clinical exposures to COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Varghese</LastName><ForeName>George M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>John</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manesh</LastName><ForeName>Abi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karthik</LastName><ForeName>Rajiv</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>O C</ForeName><Initials>OC</Initials><AffiliationInfo><Affiliation>Department of General Medicine & Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Med Res</MedlineTA><NlmUniqueID>0374701</NlmUniqueID><ISSNLinking>0971-5916</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705128">COVID-19 serotherapy</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058109" MajorTopicYN="N">Airway Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062072" MajorTopicYN="N">Patient Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012769" MajorTopicYN="N">Shock</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013048" MajorTopicYN="N">Specimen Handling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063189" MajorTopicYN="N">Symptom Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035862" MajorTopicYN="N">Vulnerable Populations</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical management - corticosteroids - COVID-19 - hydroxychloroquine - lopinavir - remdesivir - risk groups - SARS-CoV-2</Keyword></KeywordList><CoiStatement>None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32611911</ArticleId><ArticleId IdType="pii">IndianJMedRes_2020_151_5_401_285357</ArticleId><ArticleId IdType="doi">10.4103/ijmr.IJMR_957_20</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Inde</li></country></list><tree><country name="Inde"><noRegion><name sortKey="Varghese, George M" sort="Varghese, George M" uniqKey="Varghese G" first="George M" last="Varghese">George M. Varghese</name></noRegion><name sortKey="Abraham, O C" sort="Abraham, O C" uniqKey="Abraham O" first="O C" last="Abraham">O C Abraham</name><name sortKey="John, Rebecca" sort="John, Rebecca" uniqKey="John R" first="Rebecca" last="John">Rebecca John</name><name sortKey="Karthik, Rajiv" sort="Karthik, Rajiv" uniqKey="Karthik R" first="Rajiv" last="Karthik">Rajiv Karthik</name><name sortKey="Manesh, Abi" sort="Manesh, Abi" uniqKey="Manesh A" first="Abi" last="Manesh">Abi Manesh</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000267 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000267 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CardioCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32611911
|texte= Clinical management of COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32611911" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CardioCovidV1
| This area was generated with Dilib version V0.6.35. |  |